PeptideStack
5.2kquestions
20kanswers
220users

What does SURPASS-2 actually establish about mazdutide?

Asked 25 May 2026Modified 2 months agoViewed 385 times
This question was closed as needing more focus.Closed 25 Jun 2026. Answers already posted are preserved; new answers are not accepted. Questions here should ask one identifiable thing.
1

What I am working with: SURPASS-2 · mazdutide.

I have read the primary source rather than the summary, which has left me with more questions.

I understand the headline. I do not understand the footnotes, and the footnotes look important.

How should I read this, and where are the traps?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionscardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

111 questions
shareeditfollowflag
BA
askedben_akintola14k2825 May 2026
7Thank you — the worked example is what makes this usable. – meniscus_film 2 months ago
8Related: the same reasoning applies to the counter-ion question. – coldpack_88 4 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 385 times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.